227 related articles for article (PubMed ID: 30717901)
1. Conventional Radioiodine Therapy for Differentiated Thyroid Cancer.
Ylli D; Van Nostrand D; Wartofsky L
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):181-197. PubMed ID: 30717901
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine in the treatment of thyroid cancer.
Van Nostrand D; Wartofsky L
Endocrinol Metab Clin North Am; 2007 Sep; 36(3):807-22, vii-viii. PubMed ID: 17673129
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry and thyroid cancer: the individual dosage of radioiodine.
Lassmann M; Reiners C; Luster M
Endocr Relat Cancer; 2010 Sep; 17(3):R161-72. PubMed ID: 20448022
[TBL] [Abstract][Full Text] [Related]
4. Controversies, Consensus, and Collaboration in the Use of
Tuttle RM; Ahuja S; Avram AM; Bernet VJ; Bourguet P; Daniels GH; Dillehay G; Draganescu C; Flux G; Führer D; Giovanella L; Greenspan B; Luster M; Muylle K; Smit JWA; Van Nostrand D; Verburg FA; Hegedüs L
Thyroid; 2019 Apr; 29(4):461-470. PubMed ID: 30900516
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer.
Padma S; Sundaram PS
J Cancer Res Ther; 2016; 12(3):1109-1113. PubMed ID: 28054519
[TBL] [Abstract][Full Text] [Related]
6. Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer.
Van Nostrand D
Endocrinol Metab Clin North Am; 2017 Sep; 46(3):783-793. PubMed ID: 28760238
[TBL] [Abstract][Full Text] [Related]
7. Postoperative use of radioiodine (131-I): review of recommendations and guidelines.
Prpić M; Jukić T; Murgić J; Borić M; Stanicić J; Kusić Z
Coll Antropol; 2011 Jun; 35(2):587-94. PubMed ID: 21755735
[TBL] [Abstract][Full Text] [Related]
8. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4].
Dietlein M; Eschner W; Grünwald F; Lassmann M; Verburg FA; Luster M
Nuklearmedizin; 2016 Jun; 55(3):77-89. PubMed ID: 27350004
[TBL] [Abstract][Full Text] [Related]
9. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for radioiodine therapy of differentiated thyroid cancer.
Luster M; Clarke SE; Dietlein M; Lassmann M; Lind P; Oyen WJ; Tennvall J; Bombardieri E;
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1941-59. PubMed ID: 18670773
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
Berg G; Lindstedt G; Suurküla M; Jansson S
J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
[TBL] [Abstract][Full Text] [Related]
12. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin in the development and management of differentiated thyroid cancer.
McLeod DS
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):367-83. PubMed ID: 24891167
[TBL] [Abstract][Full Text] [Related]
14. The use of dosimetry in the treatment of differentiated thyroid cancer.
Lassmann M; Hänscheid H; Verburg FA; Luster M
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):107-15. PubMed ID: 21386785
[TBL] [Abstract][Full Text] [Related]
15. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
16. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Mallick U; Harmer C; Yap B; Wadsley J; Clarke S; Moss L; Nicol A; Clark PM; Farnell K; McCready R; Smellie J; Franklyn JA; John R; Nutting CM; Newbold K; Lemon C; Gerrard G; Abdel-Hamid A; Hardman J; Macias E; Roques T; Whitaker S; Vijayan R; Alvarez P; Beare S; Forsyth S; Kadalayil L; Hackshaw A
N Engl J Med; 2012 May; 366(18):1674-85. PubMed ID: 22551128
[TBL] [Abstract][Full Text] [Related]
17. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
Dietlein M; Dressler J; Eschner W; Grünwald F; Lassmann M; Leisner B; Luster M; Moser E; Reiners C; Schicha H; Schober O; ;
Nuklearmedizin; 2007; 46(5):213-9. PubMed ID: 17938757
[TBL] [Abstract][Full Text] [Related]
18. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.
Pryma DA; Mandel SJ
J Nucl Med; 2014 Sep; 55(9):1485-91. PubMed ID: 25134528
[TBL] [Abstract][Full Text] [Related]
20. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH.
Lassmann M; Hänscheid H; Reiners C; Thomas SR
J Nucl Med; 2005 May; 46(5):900-1; author reply 901. PubMed ID: 15872369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
